CMC Consulting for Viral Vectors

An effective CMC strategy for advanced therapeutics and complex biologics integrates a forward-looking regulatory, manufacturing and analytical framework from the earliest stages. Applying proven intelligence in CMC planning accelerates the path to IND for next-generation therapies by aligning manufacturing processes with preclinical objectives and long-term clinical viability.

A standard template for vector development does not exist. The manufacturing and analytical strategy for a high-performing adeno-associated viral platform will differ substantially from that of a lentiviral vector intended for ex vivo cell transduction. Our approach is tailored to the specific modality, mode of action and application.

Aligning Manufacturing with Preclinical Data

Translational data from preclinical evaluations directly informs required product attributes for a vector. The development of novel recombinant AAV serotypes, for example, expands the toolkit for achieving targeted and efficient gene delivery across diverse tissues (PMID: 15975006). The selection of a specific capsid based on this type of preclinical data has direct consequences for CMC, influencing everything from upstream production yields to the downstream purification process. A proactive CMC strategy anticipates these dependencies, building a manufacturing process tailored to the unique properties of the chosen vector without delaying timelines. This approach is informed through an enormous dataset of historical program experience.

Our consulting services focus on creating a cohesive development pathway that integrates these functions:

• Phase-Appropriate Process Design: Defining scalable upstream and downstream processes for adherent or suspension-based systems that meet the material demands of each development stage.
• Robust Analytical Framework: Establishing and qualifying assays for identity, purity, potency, and quantity that will support regulatory submissions under GXP conditions.
• Plasmid Strategy & Management: Ensuring the quality, traceability, and supply of plasmid starting materials for AAV and lentiviral production.
• Regulatory Submission Support: Assembling the comprehensive data package required for successful IND and IMPD submissions, backed by our core scientific team’s 100% successful IND rate since 2019.